Find clinical trials

LY4152199 is a human BAFF-R×CD3 bispecific antibody that engages BAFF-R on the surface of B-cells and CD3 on the surface of T-cells, with the goal of T-cell-mediated elimination of BAFF-R expressing malignant B-cells. Cohort A will assess the safety, tolerability, PK, and preliminary efficacy of escalating doses of LY4152199, administered via intravenous (IV) infusion, in participants with select relapsed/refractory B-cell malignancies. Cohort B will further assess the safety, tolerability, PK, and preliminary efficacy of LY4152199 in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

This is a 16-week double blind study to evaluate the safety and effectiveness of an oral investigational study drug in adults with cutaneous sarcoidosis (CS), a condition where inflammatory disease affects the skin. Eligible participants will be randomly assigned to receive the study drug or placebo for 16 weeks. After this period, all participants will receive the study drug for 36 weeks. What is involved? A screening period of up to 30 days to check eligibility; A 16-week treatment period where participants receive either the study drug or placebo; A 36-week open-label extension period where all participants receive the study drug; A 4-week safety follow-up after treatment ends; Regular clinic visits for safety checks and physical assessments; Possible tapering of oral corticosteroids during the study, if applicable; Blood and urine tests to monitor safety and treatment response; Completion of questionnaires and clinical assessments related to skin disease and quality of life.

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study aims to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C0902 in participants with advanced solid tumors. The study will be conducted in 2 phases: Phase 1a (dose escalation and safety expansion) and Phase 1b (dose expansion).